Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children

Aims/hypothesis During the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden and Finland. The vaccination was found to cause narcolepsy in children and young adults with the HLA-DQ 6.2 haplotype. The aim of this stud...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetologia Ročník 61; číslo 1; s. 193 - 202
Hlavní autoři: Elding Larsson, Helena, Lynch, Kristian F., Lönnrot, Maria, Haller, Michael J., Lernmark, Åke, Hagopian, William A., She, Jin-Xiong, Simell, Olli, Toppari, Jorma, Ziegler, Anette-G., Akolkar, Beena, Krischer, Jeffrey P., Rewers, Marian J., Hyöty, Heikki
Médium: Journal Article
Jazyk:angličtina
Vydáno: Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2018
Springer Nature B.V
Témata:
ISSN:0012-186X, 1432-0428, 1432-0428
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Aims/hypothesis During the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden and Finland. The vaccination was found to cause narcolepsy in children and young adults with the HLA-DQ 6.2 haplotype. The aim of this study was to investigate if exposure to Pandemrix® similarly increased the risk of islet autoimmunity or type 1 diabetes. Methods In The Environmental Determinants of Diabetes in the Young (TEDDY) study, children are followed prospectively for the development of islet autoimmunity and type 1 diabetes. In October 2009, when the mass vaccination began, 3401 children at risk for islet autoimmunity and type 1 diabetes were followed in Sweden and Finland. Vaccinations were recorded and autoantibodies against insulin, GAD65 and insulinoma-associated protein 2 were ascertained quarterly before the age of 4 years and semi-annually thereafter. Results By 5 August 2010, 2413 of the 3401 (71%) children observed as at risk for an islet autoantibody or type 1 diabetes on 1 October 2009 had been vaccinated with Pandemrix®. By 31 July 2016, 232 children had at least one islet autoantibody before 10 years of age, 148 had multiple islet autoantibodies and 96 had developed type 1 diabetes. The risk of islet autoimmunity was not increased among vaccinated children. The HR (95% CI) for the appearance of at least one islet autoantibody was 0.75 (0.55, 1.03), at least two autoantibodies was 0.85 (0.57, 1.26) and type 1 diabetes was 0.67 (0.42, 1.07). In Finland, but not in Sweden, vaccinated children had a lower risk of islet autoimmunity (0.47 [0.29, 0.75]), multiple autoantibodies (0.50 [0.28, 0.90]) and type 1 diabetes (0.38 [0.20, 0.72]) compared with those who did not receive Pandemrix®. The analyses were adjusted for confounding factors. Conclusions/interpretation Children with an increased genetic risk for type 1 diabetes who received the Pandemrix® vaccine during the A/H1N1 2009 pandemic had no increased risk of islet autoimmunity, multiple islet autoantibodies or type 1 diabetes. In Finland, the vaccine was associated with a reduced risk of islet autoimmunity and type 1 diabetes.
AbstractList During the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden and Finland. The vaccination was found to cause narcolepsy in children and young adults with the HLA-DQ 6.2 haplotype. The aim of this study was to investigate if exposure to Pandemrix® similarly increased the risk of islet autoimmunity or type 1 diabetes.AIMS/HYPOTHESISDuring the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden and Finland. The vaccination was found to cause narcolepsy in children and young adults with the HLA-DQ 6.2 haplotype. The aim of this study was to investigate if exposure to Pandemrix® similarly increased the risk of islet autoimmunity or type 1 diabetes.In The Environmental Determinants of Diabetes in the Young (TEDDY) study, children are followed prospectively for the development of islet autoimmunity and type 1 diabetes. In October 2009, when the mass vaccination began, 3401 children at risk for islet autoimmunity and type 1 diabetes were followed in Sweden and Finland. Vaccinations were recorded and autoantibodies against insulin, GAD65 and insulinoma-associated protein 2 were ascertained quarterly before the age of 4 years and semi-annually thereafter.METHODSIn The Environmental Determinants of Diabetes in the Young (TEDDY) study, children are followed prospectively for the development of islet autoimmunity and type 1 diabetes. In October 2009, when the mass vaccination began, 3401 children at risk for islet autoimmunity and type 1 diabetes were followed in Sweden and Finland. Vaccinations were recorded and autoantibodies against insulin, GAD65 and insulinoma-associated protein 2 were ascertained quarterly before the age of 4 years and semi-annually thereafter.By 5 August 2010, 2413 of the 3401 (71%) children observed as at risk for an islet autoantibody or type 1 diabetes on 1 October 2009 had been vaccinated with Pandemrix®. By 31 July 2016, 232 children had at least one islet autoantibody before 10 years of age, 148 had multiple islet autoantibodies and 96 had developed type 1 diabetes. The risk of islet autoimmunity was not increased among vaccinated children. The HR (95% CI) for the appearance of at least one islet autoantibody was 0.75 (0.55, 1.03), at least two autoantibodies was 0.85 (0.57, 1.26) and type 1 diabetes was 0.67 (0.42, 1.07). In Finland, but not in Sweden, vaccinated children had a lower risk of islet autoimmunity (0.47 [0.29, 0.75]), multiple autoantibodies (0.50 [0.28, 0.90]) and type 1 diabetes (0.38 [0.20, 0.72]) compared with those who did not receive Pandemrix®. The analyses were adjusted for confounding factors.RESULTSBy 5 August 2010, 2413 of the 3401 (71%) children observed as at risk for an islet autoantibody or type 1 diabetes on 1 October 2009 had been vaccinated with Pandemrix®. By 31 July 2016, 232 children had at least one islet autoantibody before 10 years of age, 148 had multiple islet autoantibodies and 96 had developed type 1 diabetes. The risk of islet autoimmunity was not increased among vaccinated children. The HR (95% CI) for the appearance of at least one islet autoantibody was 0.75 (0.55, 1.03), at least two autoantibodies was 0.85 (0.57, 1.26) and type 1 diabetes was 0.67 (0.42, 1.07). In Finland, but not in Sweden, vaccinated children had a lower risk of islet autoimmunity (0.47 [0.29, 0.75]), multiple autoantibodies (0.50 [0.28, 0.90]) and type 1 diabetes (0.38 [0.20, 0.72]) compared with those who did not receive Pandemrix®. The analyses were adjusted for confounding factors.Children with an increased genetic risk for type 1 diabetes who received the Pandemrix® vaccine during the A/H1N1 2009 pandemic had no increased risk of islet autoimmunity, multiple islet autoantibodies or type 1 diabetes. In Finland, the vaccine was associated with a reduced risk of islet autoimmunity and type 1 diabetes.CONCLUSIONS/INTERPRETATIONChildren with an increased genetic risk for type 1 diabetes who received the Pandemrix® vaccine during the A/H1N1 2009 pandemic had no increased risk of islet autoimmunity, multiple islet autoantibodies or type 1 diabetes. In Finland, the vaccine was associated with a reduced risk of islet autoimmunity and type 1 diabetes.
Aims/hypothesis: During the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden and Finland. The vaccination was found to cause narcolepsy in children and young adults with the HLA-DQ 6.2 haplotype. The aim of this study was to investigate if exposure to Pandemrix® similarly increased the risk of islet autoimmunity or type 1 diabetes. Methods: In The Environmental Determinants of Diabetes in the Young (TEDDY) study, children are followed prospectively for the development of islet autoimmunity and type 1 diabetes. In October 2009, when the mass vaccination began, 3401 children at risk for islet autoimmunity and type 1 diabetes were followed in Sweden and Finland. Vaccinations were recorded and autoantibodies against insulin, GAD65 and insulinoma-associated protein 2 were ascertained quarterly before the age of 4 years and semi-annually thereafter. Results: By 5 August 2010, 2413 of the 3401 (71%) children observed as at risk for an islet autoantibody or type 1 diabetes on 1 October 2009 had been vaccinated with Pandemrix®. By 31 July 2016, 232 children had at least one islet autoantibody before 10 years of age, 148 had multiple islet autoantibodies and 96 had developed type 1 diabetes. The risk of islet autoimmunity was not increased among vaccinated children. The HR (95% CI) for the appearance of at least one islet autoantibody was 0.75 (0.55, 1.03), at least two autoantibodies was 0.85 (0.57, 1.26) and type 1 diabetes was 0.67 (0.42, 1.07). In Finland, but not in Sweden, vaccinated children had a lower risk of islet autoimmunity (0.47 [0.29, 0.75]), multiple autoantibodies (0.50 [0.28, 0.90]) and type 1 diabetes (0.38 [0.20, 0.72]) compared with those who did not receive Pandemrix®. The analyses were adjusted for confounding factors. Conclusions/interpretation: Children with an increased genetic risk for type 1 diabetes who received the Pandemrix® vaccine during the A/H1N1 2009 pandemic had no increased risk of islet autoimmunity, multiple islet autoantibodies or type 1 diabetes. In Finland, the vaccine was associated with a reduced risk of islet autoimmunity and type 1 diabetes.
During the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden and Finland. The vaccination was found to cause narcolepsy in children and young adults with the HLA-DQ 6.2 haplotype. The aim of this study was to investigate if exposure to Pandemrix® similarly increased the risk of islet autoimmunity or type 1 diabetes. In The Environmental Determinants of Diabetes in the Young (TEDDY) study, children are followed prospectively for the development of islet autoimmunity and type 1 diabetes. In October 2009, when the mass vaccination began, 3401 children at risk for islet autoimmunity and type 1 diabetes were followed in Sweden and Finland. Vaccinations were recorded and autoantibodies against insulin, GAD65 and insulinoma-associated protein 2 were ascertained quarterly before the age of 4 years and semi-annually thereafter. By 5 August 2010, 2413 of the 3401 (71%) children observed as at risk for an islet autoantibody or type 1 diabetes on 1 October 2009 had been vaccinated with Pandemrix®. By 31 July 2016, 232 children had at least one islet autoantibody before 10 years of age, 148 had multiple islet autoantibodies and 96 had developed type 1 diabetes. The risk of islet autoimmunity was not increased among vaccinated children. The HR (95% CI) for the appearance of at least one islet autoantibody was 0.75 (0.55, 1.03), at least two autoantibodies was 0.85 (0.57, 1.26) and type 1 diabetes was 0.67 (0.42, 1.07). In Finland, but not in Sweden, vaccinated children had a lower risk of islet autoimmunity (0.47 [0.29, 0.75]), multiple autoantibodies (0.50 [0.28, 0.90]) and type 1 diabetes (0.38 [0.20, 0.72]) compared with those who did not receive Pandemrix®. The analyses were adjusted for confounding factors. Children with an increased genetic risk for type 1 diabetes who received the Pandemrix® vaccine during the A/H1N1 2009 pandemic had no increased risk of islet autoimmunity, multiple islet autoantibodies or type 1 diabetes. In Finland, the vaccine was associated with a reduced risk of islet autoimmunity and type 1 diabetes.
Aims/hypothesis During the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden and Finland. The vaccination was found to cause narcolepsy in children and young adults with the HLA-DQ 6.2 haplotype. The aim of this study was to investigate if exposure to Pandemrix® similarly increased the risk of islet autoimmunity or type 1 diabetes. Methods In The Environmental Determinants of Diabetes in the Young (TEDDY) study, children are followed prospectively for the development of islet autoimmunity and type 1 diabetes. In October 2009, when the mass vaccination began, 3401 children at risk for islet autoimmunity and type 1 diabetes were followed in Sweden and Finland. Vaccinations were recorded and autoantibodies against insulin, GAD65 and insulinoma-associated protein 2 were ascertained quarterly before the age of 4 years and semi-annually thereafter. Results By 5 August 2010, 2413 of the 3401 (71%) children observed as at risk for an islet autoantibody or type 1 diabetes on 1 October 2009 had been vaccinated with Pandemrix®. By 31 July 2016, 232 children had at least one islet autoantibody before 10 years of age, 148 had multiple islet autoantibodies and 96 had developed type 1 diabetes. The risk of islet autoimmunity was not increased among vaccinated children. The HR (95% CI) for the appearance of at least one islet autoantibody was 0.75 (0.55, 1.03), at least two autoantibodies was 0.85 (0.57, 1.26) and type 1 diabetes was 0.67 (0.42, 1.07). In Finland, but not in Sweden, vaccinated children had a lower risk of islet autoimmunity (0.47 [0.29, 0.75]), multiple autoantibodies (0.50 [0.28, 0.90]) and type 1 diabetes (0.38 [0.20, 0.72]) compared with those who did not receive Pandemrix®. The analyses were adjusted for confounding factors. Conclusions/interpretation Children with an increased genetic risk for type 1 diabetes who received the Pandemrix® vaccine during the A/H1N1 2009 pandemic had no increased risk of islet autoimmunity, multiple islet autoantibodies or type 1 diabetes. In Finland, the vaccine was associated with a reduced risk of islet autoimmunity and type 1 diabetes.
Aims/hypothesisDuring the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden and Finland. The vaccination was found to cause narcolepsy in children and young adults with the HLA-DQ 6.2 haplotype. The aim of this study was to investigate if exposure to Pandemrix® similarly increased the risk of islet autoimmunity or type 1 diabetes.MethodsIn The Environmental Determinants of Diabetes in the Young (TEDDY) study, children are followed prospectively for the development of islet autoimmunity and type 1 diabetes. In October 2009, when the mass vaccination began, 3401 children at risk for islet autoimmunity and type 1 diabetes were followed in Sweden and Finland. Vaccinations were recorded and autoantibodies against insulin, GAD65 and insulinoma-associated protein 2 were ascertained quarterly before the age of 4 years and semi-annually thereafter.ResultsBy 5 August 2010, 2413 of the 3401 (71%) children observed as at risk for an islet autoantibody or type 1 diabetes on 1 October 2009 had been vaccinated with Pandemrix®. By 31 July 2016, 232 children had at least one islet autoantibody before 10 years of age, 148 had multiple islet autoantibodies and 96 had developed type 1 diabetes. The risk of islet autoimmunity was not increased among vaccinated children. The HR (95% CI) for the appearance of at least one islet autoantibody was 0.75 (0.55, 1.03), at least two autoantibodies was 0.85 (0.57, 1.26) and type 1 diabetes was 0.67 (0.42, 1.07). In Finland, but not in Sweden, vaccinated children had a lower risk of islet autoimmunity (0.47 [0.29, 0.75]), multiple autoantibodies (0.50 [0.28, 0.90]) and type 1 diabetes (0.38 [0.20, 0.72]) compared with those who did not receive Pandemrix®. The analyses were adjusted for confounding factors.Conclusions/interpretationChildren with an increased genetic risk for type 1 diabetes who received the Pandemrix® vaccine during the A/H1N1 2009 pandemic had no increased risk of islet autoimmunity, multiple islet autoantibodies or type 1 diabetes. In Finland, the vaccine was associated with a reduced risk of islet autoimmunity and type 1 diabetes.
Author Krischer, Jeffrey P.
Elding Larsson, Helena
Hagopian, William A.
Toppari, Jorma
Rewers, Marian J.
Lönnrot, Maria
She, Jin-Xiong
Lynch, Kristian F.
Haller, Michael J.
Simell, Olli
Ziegler, Anette-G.
Hyöty, Heikki
Akolkar, Beena
Lernmark, Åke
Author_xml – sequence: 1
  givenname: Helena
  surname: Elding Larsson
  fullname: Elding Larsson, Helena
  email: helena.larsson@med.lu.se
  organization: Department of Clinical Sciences Malmö, Lund University CRC, Skåne University Hospital SUS
– sequence: 2
  givenname: Kristian F.
  surname: Lynch
  fullname: Lynch, Kristian F.
  organization: Health Informatics Institute, Morsani College of Medicine, University of South Florida
– sequence: 3
  givenname: Maria
  surname: Lönnrot
  fullname: Lönnrot, Maria
  organization: Faculty of Medicine and Life Sciences, University of Tampere, Department of Dermatology, Tampere University Hospital
– sequence: 4
  givenname: Michael J.
  surname: Haller
  fullname: Haller, Michael J.
  organization: Department of Pediatrics, University of Florida
– sequence: 5
  givenname: Åke
  surname: Lernmark
  fullname: Lernmark, Åke
  organization: Department of Clinical Sciences Malmö, Lund University CRC, Skåne University Hospital SUS
– sequence: 6
  givenname: William A.
  surname: Hagopian
  fullname: Hagopian, William A.
  organization: Pacific Northwest Diabetes Research Institute
– sequence: 7
  givenname: Jin-Xiong
  surname: She
  fullname: She, Jin-Xiong
  organization: Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University
– sequence: 8
  givenname: Olli
  surname: Simell
  fullname: Simell, Olli
  organization: Department of Pediatrics, Turku University Hospital
– sequence: 9
  givenname: Jorma
  surname: Toppari
  fullname: Toppari, Jorma
  organization: Department of Pediatrics, Turku University Hospital, Department of Physiology, Institute of Biomedicine, University of Turku
– sequence: 10
  givenname: Anette-G.
  surname: Ziegler
  fullname: Ziegler, Anette-G.
  organization: Institute of Diabetes Research, Helmholtz Zentrum München, and Klinikum rechts der Isar, Technische Universität München, Forschergruppe Diabetes e.V
– sequence: 11
  givenname: Beena
  surname: Akolkar
  fullname: Akolkar, Beena
  organization: National Institute of Diabetes & Digestive & Kidney Diseases
– sequence: 12
  givenname: Jeffrey P.
  surname: Krischer
  fullname: Krischer, Jeffrey P.
  organization: Health Informatics Institute, Morsani College of Medicine, University of South Florida
– sequence: 13
  givenname: Marian J.
  surname: Rewers
  fullname: Rewers, Marian J.
  organization: Barbara Davis Center for Childhood Diabetes, University of Colorado
– sequence: 14
  givenname: Heikki
  surname: Hyöty
  fullname: Hyöty, Heikki
  organization: Faculty of Medicine and Life Sciences, University of Tampere, Fimlab Laboratories, Pirkanmaa Hospital District
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28990147$$D View this record in MEDLINE/PubMed
BookMark eNp9kstuFSEcxiemxl70AdwYEjduRmFgBtiYmLZekia6qImuCAP_6aHOwBGY1rP1gXwIn0zOxaZtoitC-H3f_8J3WO354KGqnhL8kmDMXyWMSdPWmPCaMSZq-qA6IIw2NWaN2KsO1s81Ed2X_eowpUuMMW1Z96jab4SUmDB-UP38pL2FKbofv3-hK22M8zq74JFLyIeMdErBOJ3BomuXF8h5E0Gnco0ufUNhKOAIhZtzcNM0e5dXKESUV0tABFmne8iQig7lBaDz05OTryjl2a6QWbjRRvCPq4eDHhM82Z1H1ee3p-fH7-uzj-8-HL85q03b4VxLPXSYyJb2XA6sN7y3bZmhk6C5ZVxyACG55qS3nRDQSdoOzBo7aEqsoC09qvTWN13Dcu7VMrpJx5UK2qlliFmPKkICHc1CjbNKoAo1OrPZR1K8NZR1hCpjrVGs70EJa4kSIDtNaNMOtCk1Xm9rFOkE1oDPsfjeKXXnxbuFughXquWcdR0uBi92BjF8nyFlNblkYBy1hzAnRSSTWEjRioI-v4dehjn6ssJCcUoZk5upn93u6KaVvxEoANkCJoaUIgw3CMFqHTO1jZkqMVPrmClaNPyexri82VMZyo3_VTa7TyhV_AXEW03_U_QHi-7qww
CitedBy_id crossref_primary_10_1016_j_diabres_2020_108372
crossref_primary_10_1111_joim_13648
crossref_primary_10_3389_fimmu_2021_737964
crossref_primary_10_3390_vaccines12040384
crossref_primary_10_2196_63161
crossref_primary_10_1016_j_atherosclerosis_2025_120405
crossref_primary_10_1007_s00125_018_4662_7
crossref_primary_10_3390_ijms22147493
crossref_primary_10_3389_fendo_2022_1027047
crossref_primary_10_1007_s40278_017_37780_8
crossref_primary_10_1111_jdi_13387
crossref_primary_10_1038_s41574_024_01045_0
crossref_primary_10_3390_vaccines11091419
crossref_primary_10_1111_jdi_13540
crossref_primary_10_3390_vaccines13010050
crossref_primary_10_1007_s11892_018_1113_2
crossref_primary_10_1111_ane_13633
crossref_primary_10_7554_eLife_88231
crossref_primary_10_1136_bmjopen_2024_084808
Cites_doi 10.1210/jc.2010-0293
10.1371/journal.pone.0114361
10.1111/j.1399-5448.2011.00774.x
10.1001/jama.2013.6285
10.2165/00002018-199920030-00001
10.1111/joim.12150
10.1093/sleep/33.11.1428
10.1111/sji.12138
10.1089/dia.2007.0229
10.2337/db14-1497
10.2337/dc14-S014
10.1371/journal.pone.0033536
10.1016/S0140-6736(16)30582-7
10.1001/jamapediatrics.2015.2757
10.1371/journal.pone.0033723
10.1196/annals.1447.062
10.1111/joim.12583
10.1007/s00125-015-3514-y
10.1111/joim.12246
10.1007/s00125-015-3800-8
10.1007/s11892-013-0433-5
10.1016/S0140-6736(16)30507-4
10.1177/039463201102400311
10.1016/j.vaccine.2008.06.057
10.1111/joim.12245
10.1007/s00125-015-3723-4
10.1038/srep27887
10.1002/dmrr.1014
ContentType Journal Article
Copyright The Author(s) 2017
Diabetologia is a copyright of Springer, (2017). All Rights Reserved.
Copyright_xml – notice: The Author(s) 2017
– notice: Diabetologia is a copyright of Springer, (2017). All Rights Reserved.
CorporateAuthor for the TEDDY Study Group
TEDDY Study Group
Strategiska forskningsområden (SFO)
EXODIAB: Excellence of Diabetes Research in Sweden
Faculty of Medicine
Strategic research areas (SRA)
Lunds universitet
Profile areas and other strong research environments
Department of Clinical Sciences, Malmö
Medicinska fakulteten
Lund University
Profilområden och andra starka forskningsmiljöer
Institutionen för kliniska vetenskaper, Malmö
CorporateAuthor_xml – name: for the TEDDY Study Group
– name: TEDDY Study Group
– name: Faculty of Medicine
– name: Medicinska fakulteten
– name: Strategiska forskningsområden (SFO)
– name: Profilområden och andra starka forskningsmiljöer
– name: Lund University
– name: EXODIAB: Excellence of Diabetes Research in Sweden
– name: Profile areas and other strong research environments
– name: Institutionen för kliniska vetenskaper, Malmö
– name: Strategic research areas (SRA)
– name: Lunds universitet
– name: Department of Clinical Sciences, Malmö
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8AO
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTPV
AGCHP
AOWAS
D8T
D95
ZZAVC
DOI 10.1007/s00125-017-4448-3
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SWEPUB Lunds universitet full text
SwePub Articles
SWEPUB Freely available online
SWEPUB Lunds universitet
SwePub Articles full text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE

ProQuest One Academic Middle East (New)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-0428
EndPage 202
ExternalDocumentID oai_portal_research_lu_se_publications_75c34613_cddc_4bbe_8dd1_8e96a1325f32
PMC5774660
28990147
10_1007_s00125_017_4448_3
Genre Journal Article
GeographicLocations Sweden
Finland
GeographicLocations_xml – name: Finland
– name: Sweden
GrantInformation_xml – fundername: National Institute of Child Health and Human Development
  funderid: http://dx.doi.org/10.13039/100000071
– fundername: NIH/NCATS Clinical and Translational Science Awards to the University of Colorado Boulder
  grantid: U01 DK63861, Contract No. HHSN267200700014C, U01 DK63790, U01 DK63821, U01 DK63829, U01 DK63836, U01 DK63863, U01 DK63865, UC4 DK100238, UC4 DK106955, UC4 DK63821, UC4 DK63829, UC4 DK63836, UC4 DK63861, UC4 DK63863, UC4 DK63865, UC4 DK95300
– fundername: Centers for Disease Control and Prevention
  funderid: http://dx.doi.org/10.13039/100000030
– fundername: the NIH/NCATS Clinical and Translational Science Awards to the University of Florida
  grantid: UL1 TR000064
– fundername: National Institute of Environmental Health Sciences
  funderid: http://dx.doi.org/10.13039/100000066
– fundername: National Institute of Diabetes and Digestive and Kidney Diseases
  grantid: UC4 DK95300
  funderid: http://dx.doi.org/10.13039/100000062
– fundername: National Institute of Allergy and Infectious Diseases
  funderid: http://dx.doi.org/10.13039/100000060
– fundername: Juvenile Diabetes Research Foundation
  funderid: http://dx.doi.org/10.13039/100008664
– fundername: NIDDK NIH HHS
  grantid: P30 DK017047
– fundername: NIDDK NIH HHS
  grantid: U01 DK063861
– fundername: NIDDK NIH HHS
  grantid: UC4 DK063836
– fundername: NIDDK NIH HHS
  grantid: U01 DK063865
– fundername: NIDDK NIH HHS
  grantid: U01 DK063821
– fundername: NIDDK NIH HHS
  grantid: UC4 DK112243
– fundername: NIDDK NIH HHS
  grantid: UC4 DK95300
– fundername: NIDDK NIH HHS
  grantid: U01 DK063829
– fundername: NIDDK NIH HHS
  grantid: UC4 DK063821
– fundername: NIDDK NIH HHS
  grantid: UC4 DK063861
– fundername: ;
– fundername: ;
  grantid: UC4 DK95300
– fundername: ;
  grantid: UL1 TR000064
– fundername: ;
  grantid: U01 DK63861, Contract No. HHSN267200700014C, U01 DK63790, U01 DK63821, U01 DK63829, U01 DK63836, U01 DK63863, U01 DK63865, UC4 DK100238, UC4 DK106955, UC4 DK63821, UC4 DK63829, UC4 DK63836, UC4 DK63861, UC4 DK63863, UC4 DK63865, UC4 DK95300
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.55
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1CY
1N0
1SB
2.D
203
28-
29F
29G
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3O-
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
78A
7X7
88E
8AO
8C1
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
A8Z
AAAVM
AABHQ
AACDK
AAEWM
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABOCM
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFDYV
AFEXP
AFFNX
AFJLC
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGVAE
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
C6C
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
J5H
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
L7B
LAS
LLZTM
M1P
M4Y
MA-
MVM
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P6G
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
ROL
RPX
RRX
RSV
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TR2
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WH7
WJK
WK8
X7M
YLTOR
Z45
Z7U
Z7V
Z7W
Z82
Z83
Z87
Z8O
Z8P
Z8Q
Z8V
Z8W
Z91
Z92
ZGI
ZMTXR
ZOVNA
~EX
~KM
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
ADHKG
AEZWR
AFDZB
AFFHD
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
ESTFP
PUEGO
5PM
ADTPV
AGCHP
AOWAS
D8T
D95
ZZAVC
ID FETCH-LOGICAL-c560t-9af601953b79f4bc7bd501469ea7d4797ee897a71bd688e6935f4dcdfa31d8353
IEDL.DBID 8C1
ISICitedReferencesCount 19
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000417272300022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0012-186X
1432-0428
IngestDate Tue Nov 04 16:00:53 EST 2025
Tue Nov 04 01:58:11 EST 2025
Mon Sep 08 14:33:29 EDT 2025
Thu Nov 27 13:51:36 EST 2025
Mon Jul 21 06:04:05 EDT 2025
Tue Nov 18 22:11:22 EST 2025
Sat Nov 29 02:07:39 EST 2025
Fri Feb 21 02:35:32 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Swine flu
Type 1 diabetes
Vaccination
Islet autoimmunity
Squalene
Pandemrix
Influenza vaccine
Language English
License Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c560t-9af601953b79f4bc7bd501469ea7d4797ee897a71bd688e6935f4dcdfa31d8353
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://link.springer.com/10.1007/s00125-017-4448-3
PMID 28990147
PQID 1973344935
PQPubID 48469
PageCount 10
ParticipantIDs swepub_primary_oai_portal_research_lu_se_publications_75c34613_cddc_4bbe_8dd1_8e96a1325f32
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5774660
proquest_miscellaneous_1949089858
proquest_journals_1973344935
pubmed_primary_28990147
crossref_primary_10_1007_s00125_017_4448_3
crossref_citationtrail_10_1007_s00125_017_4448_3
springer_journals_10_1007_s00125_017_4448_3
PublicationCentury 2000
PublicationDate 2018-01-01
PublicationDateYYYYMMDD 2018-01-01
PublicationDate_xml – month: 01
  year: 2018
  text: 2018-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationSubtitle Clinical, Translational and Experimental Diabetes and Metabolism
PublicationTitle Diabetologia
PublicationTitleAbbrev Diabetologia
PublicationTitleAlternate Diabetologia
PublicationYear 2018
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References Tuomilehto (CR26) 2013; 13
Nohynek, Jokinen, Partinen (CR8) 2012; 7
Krischer, Lynch, Schatz (CR17) 2015; 58
(CR16) 2014; 37
Andersson (CR23) 2017; 281
Babaya, Yu, Miao (CR15) 2009; 25
Morgan, Halliday, Campbell, Cardwell, Patterson (CR6) 2016; 59
Hagopian, Erlich, Lernmark (CR12) 2011; 12
(CR11) 2008; 1150
Valdes, Unanue, Hernandez (CR27) 2013; 11
Hiltunen, Lonnrot, Hyoty (CR5) 1999; 20
Uusitalo, Liu, Yang (CR19) 2016; 170
Nenna, Papoff, Moretti (CR28) 2011; 24
Persson (CR24) 2014; 276
Svensson, Ramelius, Nilsson (CR25) 2014; 79
Vaarala, Vuorela, Partinen (CR10) 2014; 9
Kondrashova, Nurminen, Patrikainen (CR29) 2015; 58
Bonifacio, Yu, Williams (CR14) 2010; 95
Poland, Ovsyannikova, Jacobson (CR20) 2008; 26
Pociot, Lernmark (CR2) 2016; 387
Persson, Granath, Askling, Ludvigsson, Olsson, Feltelius (CR21) 2014; 275
Rewers, Ludvigsson (CR1) 2016; 387
Partinen, Saarenpaa-Heikkila, Ilveskoski (CR9) 2012; 7
Andersson (CR22) 2014; 276
Ziegler, Rewers, Simell (CR4) 2013; 309
Dauvilliers, Montplaisir, Cochen (CR7) 2010; 33
Kiviniemi, Hermann, Nurmi (CR13) 2007; 9
Torn, Liu, Hagopian (CR18) 2016; 6
Torn, Hadley, Lee (CR3) 2015; 64
E Bonifacio (4448_CR14) 2010; 95
M Hiltunen (4448_CR5) 1999; 20
JP Krischer (4448_CR17) 2015; 58
M Rewers (4448_CR1) 2016; 387
AG Ziegler (4448_CR4) 2013; 309
Y Dauvilliers (4448_CR7) 2010; 33
F Pociot (4448_CR2) 2016; 387
WA Hagopian (4448_CR12) 2011; 12
O Vaarala (4448_CR10) 2014; 9
C Torn (4448_CR18) 2016; 6
GA Poland (4448_CR20) 2008; 26
I Persson (4448_CR21) 2014; 275
J Tuomilehto (4448_CR26) 2013; 13
L Andersson (4448_CR23) 2017; 281
E Morgan (4448_CR6) 2016; 59
U Uusitalo (4448_CR19) 2016; 170
C Valdes (4448_CR27) 2013; 11
M Svensson (4448_CR25) 2014; 79
I Persson (4448_CR24) 2014; 276
N Babaya (4448_CR15) 2009; 25
M Kiviniemi (4448_CR13) 2007; 9
R Nenna (4448_CR28) 2011; 24
A Kondrashova (4448_CR29) 2015; 58
The TEDDY Study Group (4448_CR11) 2008; 1150
H Nohynek (4448_CR8) 2012; 7
American Diabetes Association (4448_CR16) 2014; 37
L Andersson (4448_CR22) 2014; 276
C Torn (4448_CR3) 2015; 64
M Partinen (4448_CR9) 2012; 7
References_xml – volume: 95
  start-page: 3360
  year: 2010
  end-page: 3367
  ident: CR14
  article-title: Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2010-0293
– volume: 11
  start-page: 161
  year: 2013
  end-page: 166
  ident: CR27
  article-title: Is there a link between influenza and type I diabetes? Increased incidence of TID during the pandemic H1N1 influenza of 2009 in Chile
  publication-title: Pediatr Endocrinol Rev
– volume: 9
  start-page: e114361
  year: 2014
  ident: CR10
  article-title: Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for Pandemrix-associated narcolepsy risk
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0114361
– volume: 12
  start-page: 733
  year: 2011
  end-page: 743
  ident: CR12
  article-title: The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants
  publication-title: Pediatr Diabetes
  doi: 10.1111/j.1399-5448.2011.00774.x
– volume: 309
  start-page: 2473
  year: 2013
  end-page: 2479
  ident: CR4
  article-title: Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
  publication-title: JAMA
  doi: 10.1001/jama.2013.6285
– volume: 20
  start-page: 207
  year: 1999
  end-page: 212
  ident: CR5
  article-title: Immunisation and type 1 diabetes mellitus: is there a link?
  publication-title: Drug Saf
  doi: 10.2165/00002018-199920030-00001
– volume: 275
  start-page: 172
  year: 2014
  end-page: 190
  ident: CR21
  article-title: Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up
  publication-title: J Intern Med
  doi: 10.1111/joim.12150
– volume: 33
  start-page: 1428
  year: 2010
  end-page: 1430
  ident: CR7
  article-title: Post-H1N1 narcolepsy-cataplexy
  publication-title: Sleep
  doi: 10.1093/sleep/33.11.1428
– volume: 79
  start-page: 137
  year: 2014
  end-page: 148
  ident: CR25
  article-title: Antibodies to influenza virus A/H1N1 hemagglutinin in type 1 diabetes children diagnosed before, during and after the SWEDISH A(H1N1)pdm09 vaccination campaign 2009–2010
  publication-title: Scand J Immunol
  doi: 10.1111/sji.12138
– volume: 9
  start-page: 460
  year: 2007
  end-page: 472
  ident: CR13
  article-title: A high-throughput population screening system for the estimation of genetic risk for type 1 diabetes: an application for the TEDDY (The Environmental Determinants of Diabetes in the Young) study
  publication-title: Diabetes Technol Ther
  doi: 10.1089/dia.2007.0229
– volume: 64
  start-page: 1818
  year: 2015
  end-page: 1829
  ident: CR3
  article-title: Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY study
  publication-title: Diabetes
  doi: 10.2337/db14-1497
– volume: 37
  start-page: S14
  issue: Suppl 1
  year: 2014
  end-page: S80
  ident: CR16
  article-title: Standards of medical care in diabetes—2014
  publication-title: Diabetes Care
  doi: 10.2337/dc14-S014
– volume: 7
  start-page: e33536
  year: 2012
  ident: CR8
  article-title: AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0033536
– volume: 387
  start-page: 2331
  year: 2016
  end-page: 2339
  ident: CR2
  article-title: Genetic risk factors for type 1 diabetes
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30582-7
– volume: 170
  start-page: 20
  year: 2016
  end-page: 28
  ident: CR19
  article-title: Association of early exposure of probiotics and islet autoimmunity in the TEDDY study
  publication-title: JAMA Pediatr
  doi: 10.1001/jamapediatrics.2015.2757
– volume: 7
  start-page: e33723
  year: 2012
  ident: CR9
  article-title: Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0033723
– volume: 1150
  start-page: 1
  year: 2008
  end-page: 13
  ident: CR11
  article-title: The Environmental Determinants of Diabetes in the Young (TEDDY) study
  publication-title: Ann N Y Acad Sci
  doi: 10.1196/annals.1447.062
– volume: 281
  start-page: 99
  year: 2017
  end-page: 101
  ident: CR23
  article-title: Hidden authority study data have come to light: besides narcolepsy, the swine influenza vaccine Pandemrix caused type 1 diabetes
  publication-title: J Intern Med
  doi: 10.1111/joim.12583
– volume: 58
  start-page: 980
  year: 2015
  end-page: 987
  ident: CR17
  article-title: The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study
  publication-title: Diabetologia
  doi: 10.1007/s00125-015-3514-y
– volume: 276
  start-page: 414
  year: 2014
  end-page: 417
  ident: CR22
  article-title: Contradictory data on type 1 diabetes in a recently published article ‘Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up’ (J Intern Med 2013)
  publication-title: J Intern Med
  doi: 10.1111/joim.12246
– volume: 59
  start-page: 237
  year: 2016
  end-page: 243
  ident: CR6
  article-title: Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies
  publication-title: Diabetologia
  doi: 10.1007/s00125-015-3800-8
– volume: 13
  start-page: 795
  year: 2013
  end-page: 804
  ident: CR26
  article-title: The emerging global epidemic of type 1 diabetes
  publication-title: Curr Diab Rep
  doi: 10.1007/s11892-013-0433-5
– volume: 387
  start-page: 2340
  year: 2016
  end-page: 2348
  ident: CR1
  article-title: Environmental risk factors for type 1 diabetes
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30507-4
– volume: 24
  start-page: 651
  year: 2011
  end-page: 659
  ident: CR28
  article-title: Detection of respiratory viruses in the 2009 winter season in Rome: 2009 influenza A (H1N1) complications in children and concomitant type 1 diabetes onset
  publication-title: Int J Immunopathol Pharmacol
  doi: 10.1177/039463201102400311
– volume: 26
  start-page: 6183
  year: 2008
  end-page: 6188
  ident: CR20
  article-title: Vaccine immunogenetics: bedside to bench to population
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.06.057
– volume: 276
  start-page: 413
  year: 2014
  ident: CR24
  article-title: Response to letter to the editor by Lars Andersson
  publication-title: J Intern Med
  doi: 10.1111/joim.12245
– volume: 58
  start-page: 2592
  year: 2015
  end-page: 2595
  ident: CR29
  article-title: Influenza A virus antibodies show no association with pancreatic islet autoantibodies in children genetically predisposed to type 1 diabetes
  publication-title: Diabetologia
  doi: 10.1007/s00125-015-3723-4
– volume: 6
  start-page: 27887
  year: 2016
  ident: CR18
  article-title: Complement gene variants in relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY Study
  publication-title: Sci Rep
  doi: 10.1038/srep27887
– volume: 25
  start-page: 665
  year: 2009
  end-page: 670
  ident: CR15
  article-title: Comparison of insulin autoantibody: polyethylene glycol and micro-IAA 1-day and 7-day assays
  publication-title: Diabetes Metab Res Rev
  doi: 10.1002/dmrr.1014
– volume: 37
  start-page: S14
  issue: Suppl 1
  year: 2014
  ident: 4448_CR16
  publication-title: Diabetes Care
  doi: 10.2337/dc14-S014
– volume: 6
  start-page: 27887
  year: 2016
  ident: 4448_CR18
  publication-title: Sci Rep
  doi: 10.1038/srep27887
– volume: 79
  start-page: 137
  year: 2014
  ident: 4448_CR25
  publication-title: Scand J Immunol
  doi: 10.1111/sji.12138
– volume: 26
  start-page: 6183
  year: 2008
  ident: 4448_CR20
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.06.057
– volume: 9
  start-page: e114361
  year: 2014
  ident: 4448_CR10
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0114361
– volume: 12
  start-page: 733
  year: 2011
  ident: 4448_CR12
  publication-title: Pediatr Diabetes
  doi: 10.1111/j.1399-5448.2011.00774.x
– volume: 170
  start-page: 20
  year: 2016
  ident: 4448_CR19
  publication-title: JAMA Pediatr
  doi: 10.1001/jamapediatrics.2015.2757
– volume: 387
  start-page: 2340
  year: 2016
  ident: 4448_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30507-4
– volume: 276
  start-page: 413
  year: 2014
  ident: 4448_CR24
  publication-title: J Intern Med
  doi: 10.1111/joim.12245
– volume: 20
  start-page: 207
  year: 1999
  ident: 4448_CR5
  publication-title: Drug Saf
  doi: 10.2165/00002018-199920030-00001
– volume: 281
  start-page: 99
  year: 2017
  ident: 4448_CR23
  publication-title: J Intern Med
  doi: 10.1111/joim.12583
– volume: 13
  start-page: 795
  year: 2013
  ident: 4448_CR26
  publication-title: Curr Diab Rep
  doi: 10.1007/s11892-013-0433-5
– volume: 7
  start-page: e33723
  year: 2012
  ident: 4448_CR9
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0033723
– volume: 9
  start-page: 460
  year: 2007
  ident: 4448_CR13
  publication-title: Diabetes Technol Ther
  doi: 10.1089/dia.2007.0229
– volume: 33
  start-page: 1428
  year: 2010
  ident: 4448_CR7
  publication-title: Sleep
  doi: 10.1093/sleep/33.11.1428
– volume: 58
  start-page: 980
  year: 2015
  ident: 4448_CR17
  publication-title: Diabetologia
  doi: 10.1007/s00125-015-3514-y
– volume: 7
  start-page: e33536
  year: 2012
  ident: 4448_CR8
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0033536
– volume: 276
  start-page: 414
  year: 2014
  ident: 4448_CR22
  publication-title: J Intern Med
  doi: 10.1111/joim.12246
– volume: 59
  start-page: 237
  year: 2016
  ident: 4448_CR6
  publication-title: Diabetologia
  doi: 10.1007/s00125-015-3800-8
– volume: 64
  start-page: 1818
  year: 2015
  ident: 4448_CR3
  publication-title: Diabetes
  doi: 10.2337/db14-1497
– volume: 275
  start-page: 172
  year: 2014
  ident: 4448_CR21
  publication-title: J Intern Med
  doi: 10.1111/joim.12150
– volume: 387
  start-page: 2331
  year: 2016
  ident: 4448_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30582-7
– volume: 24
  start-page: 651
  year: 2011
  ident: 4448_CR28
  publication-title: Int J Immunopathol Pharmacol
  doi: 10.1177/039463201102400311
– volume: 1150
  start-page: 1
  year: 2008
  ident: 4448_CR11
  publication-title: Ann N Y Acad Sci
  doi: 10.1196/annals.1447.062
– volume: 25
  start-page: 665
  year: 2009
  ident: 4448_CR15
  publication-title: Diabetes Metab Res Rev
  doi: 10.1002/dmrr.1014
– volume: 58
  start-page: 2592
  year: 2015
  ident: 4448_CR29
  publication-title: Diabetologia
  doi: 10.1007/s00125-015-3723-4
– volume: 95
  start-page: 3360
  year: 2010
  ident: 4448_CR14
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2010-0293
– volume: 309
  start-page: 2473
  year: 2013
  ident: 4448_CR4
  publication-title: JAMA
  doi: 10.1001/jama.2013.6285
– volume: 11
  start-page: 161
  year: 2013
  ident: 4448_CR27
  publication-title: Pediatr Endocrinol Rev
SSID ssj0003546
Score 2.3667364
Snippet Aims/hypothesis During the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in...
During the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden and Finland....
Aims/hypothesisDuring the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden...
Aims/hypothesis: During the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in...
SourceID swepub
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 193
SubjectTerms Autoantibodies
Autoantibodies - immunology
Autoantibodies - metabolism
Autoimmunity
Autoimmunity - physiology
Children
Clinical Medicine
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 1 - metabolism
Endocrinology and Diabetes
Endokrinologi och diabetes
Female
Finland
Histocompatibility antigen HLA
Human Physiology
Humans
Immunization
Influenza A Virus, H1N1 Subtype - drug effects
Influenza Vaccines - adverse effects
Insulin
Insulinoma
Internal Medicine
Klinisk medicin
Male
Medical and Health Sciences
Medicin och hälsovetenskap
Medicine
Medicine & Public Health
Metabolic Diseases
Narcolepsy
Neuroendocrine tumors
Pandemics
Sleep disorders
Squalene
Squalene - chemistry
Vaccination
Vaccines
SummonAdditionalLinks – databaseName: SpringerLINK Contemporary 1997-Present
  dbid: RSV
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwELagIMSFvTRQkJE4FVlqYsfLEQEVF6qKTQ8uVuJFjdQm1UteVa78IH4Ev4yx40R9lCLBMck43saeb2Y8Y4SeO--cYMwQyS0lIPEVCUnbSe0KxawtbOFZvGxC7O_LxUIdpDjufjrtPrkk4049B7sFyRwOmgnCQKcg9Cq6BtJOhtX4_sPnefulKToHqEku-WJyZf7pF-vC6ALCvHhQcvaW_pZZNEqjvdv_1Y876FYCn_jlyC130RXX3kM33iX3-n30_SCYlI-XzdnPH_i0MvA2Thxuetx2A67SXDqLg_0WN23AnD08hhPquPNACHyAq9XQNTHwZPiGuyUOdl6c48nOC-Uw4E4Mm-brLzgmuMVTUPkD9GnvzcdXb0m6pIEYAEsDUZXnIeiQ1kJ5VhtR2-Cq5MpVwjKhhHNSiUrkteVSOq5o6Zk11lc0twD_6CbaaLvWbSFsTEl9Ll1pQMvzMLfU1BTUMe-Mgo2IZmh3mi1tUgbzcJHGkZ5zL8ex1TC2OoythiI7c5GTMX3H34i3JxbQaSX3OoeqKWPQ7Aw9mz_DGgyOlap13SrQRPepLGWGHo4cM9cWFFoYD5EhscZLM0HI773-pW0OY57vEqA557sZejEx0rlmXd6JryNjrlcQdTmdEkgd6qOV7p0-OWcZ1qI0lAG408Zao1ldOy2tzbV0ilc5LUpPi0f_1JTH6CbASzkarLbRxrBcuSfoujkdmn75NK7aX3UoQGU
  priority: 102
  providerName: Springer Nature
Title Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children
URI https://link.springer.com/article/10.1007/s00125-017-4448-3
https://www.ncbi.nlm.nih.gov/pubmed/28990147
https://www.proquest.com/docview/1973344935
https://www.proquest.com/docview/1949089858
https://pubmed.ncbi.nlm.nih.gov/PMC5774660
Volume 61
WOSCitedRecordID wos000417272300022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1432-0428
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0003546
  issn: 1432-0428
  databaseCode: RSV
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoixAX3oWFsjISJ5DFJnZi-4SgtOLCalUeWrhYiR9qpJIsm2wFV34QP4JfxtjrpF0qeuGyUja2knjG429m7G8QemqdtZwxTURuKIEVXxJP2k5Km0pmTGpSx0KxCT6divlczmLArY3bKnubGAy1abSPkb9IJKeUMUmzl4tvxFeN8tnVWEJjC-0k6YT5iSn2z7Z40HhQB4wwSUQ-77Oak0AiCks78TaagYdC6Oa6dAFsXtwzOSRO_yIZDQvT4c3__aRb6EaEpPjVWoduoyu2voOuvYtJ97vo58wHmr8uq--_f-HTQsO_QZy4anHddLiIErYG-6gurmqPRFu49PvWceOgIWgHLlZdU4XjKN0P3Cyxj_7iBPfRX-iHAY1iMKVvPuNAe4v7o-b30MfDgw_7b0ks3UA0QKiOyMLl_igiLbl0rNS8ND6BmUtbcMO45NYKyQuelCYXwuYwBo4ZbVxBEwOgkO6i7bqp7QOEtc6oS4TNNPh-DvAN1SUFJ81ZDeM3oSM06QWndOQ19-U1TtTAyBxkrUDWystaQZdnQ5fFmtTjssZ7vfRUnN-tOhPdCD0ZbsPM9OmWorbNyrcJSVWRiRG6v1ae4WnezYXx4CPEN9RqaOBZvzfv1NVxYP_OALDn-WSEnvcKeO61_v0RX9Y6uvmA4OGpSCt1rE5WqrVqcS5erHimKQPIp7QxWrGytEoYkyhhZV4kNM0cTR9ePkKP0HVAmWIdt9pD291yZR-jq_q0q9rlGG3xOQ-_Yhxm7xjtvD6Yzo7g6uj9pz-YF09P
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFLWqgoAN78dAASPBBmQxiZ3YXiCEKFWrtqMuijSwMYkfaqSSDJNMoVs-qB_Bl3HtPOhQ0V0XLGdiyzPO8X37XISeW2ctZ0wTkRpKQONL4knbSW5jyYyJTexYaDbBJxMxncq9FXTS34XxZZW9TAyC2lTax8hfR5JTypikydvZN-K7Rvnsat9Co4XFtj3-Di5b_WZrHd7vizje-LD_fpN0XQWIBu3eEJm51N-SozmXjuWa58bn1lJpM24Yl9xaIXnGo9ykQtgUVnTMaOMyGhkRukSAyL8Ecpz7EjI-HRy8Me0uBoHQJ5FIp30WdRxIS8GUIF4nMPCICF3Wg2eM27M1mkOi9i9S06AIN278b1t4E13vTG78rj0jt9CKLW-jK7tdUcEd9HPPB9K_zosfv07wUabh2wBXXNS4rBqcdQi2BvuoNS5Kb2nX8NHX5ePKwUBAP84WTVWE6zbNMa7m2Ee3cYT76DbMw2BtY1AV659woPXF_VX6u-jjhezAPbRaVqV9gLDWCXWRsIkG39aB_UZ1TsEJdVbD-xrTERr3QFG642337UMO1cA4HbClAFvKY0vBlJfDlFlLWnLe4LUeLaqTX7X6A5URejY8Bsnj00lZaauFHxOSxiIRI3S_BeuwmnfjYT_4CPElGA8DPKv58pOyOAjs5gk4JGk6HqFXPeBP_ax__4nP7ZlYXiB4sKqjzTpQhwtVWzU7FQ9XPNGUgUmrtDFasTy3ShgTKWFlmkU0ThyNH56_Q0_R1c393R21szXZfoSugUUt2hjdGlpt5gv7GF3WR01Rz58EaYHRl4s-W78BIvuoMQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3JbtQwGLaqgiou7JSBAkaCCyhqEjuxfUAIMYyoCqM5gDRwMYkXNVJJhkmm0CsPxANw5Mn47Sx0qOitB45JbDlxPv_7gtAjY41hlKqAp5oEwPFF4Iq2B7mJBdU61rGlvtkEm075fC5mG-hnnwvjwip7mugJta6Us5HvRoIRQqkgya7twiJm48nzxZfAdZBynta-nUYLkX1z_BXUt_rZ3hj-9eM4nrx69_J10HUYCBRw-iYQmU1dxhzJmbA0VyzXzs-WCpMxTZlgxnDBMhblOuXcpLC6pVppm5FIc98xAsj_BXgz5tpGsPmg7IWkSxICBhBEPJ33HtXQFzAFsSJw_IGCdhSQdZ54StA9Ha85OG3_KnDqmeLkyv-8nVfR5U4Uxy_as3MNbZjyOtp62wUb3EDfZ87A_nlZfPv1Ax9lCu56GOOixmXV4KxDttHYWbNxUToJvIZLF6-PKwsD4VTgbNVUhU_DaY5xtcTO6o0j3Fu9YR4GKRwDCxl_wL7cL-5T7G-i9-eyA7fQZlmV5jbCSiXERtwkCnReC3IdUTkB5dQaBf8uJCMU9qCRqqvn7tqKHMqhErXHmQScSYczCVOeDFMWbTGTswbv9MiRHV2r5R_YjNDD4TFQJOdmykpTrdwY70zmCR-h7Ra4w2pOvYf9YCPE1iA9DHDVzteflMWBr3qegKKSpuEIPe3Bf-K1_v0RH9vzsb6A12xlV07rQB6uZG3k4oSdXLJEEQqirlRaK0nz3EiudSS5EWkWkTixJL5z9g49QFtwpOSbven-XXQJBG3emu520GazXJl76KI6aop6ed8TDow-nffR-g1uPbDl
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pandemrix%C2%AE+vaccination+is+not+associated+with+increased+risk+of+islet+autoimmunity+or+type+1+diabetes+in+the+TEDDY+study+children&rft.jtitle=Diabetologia&rft.au=Helena+Elding+Larsson&rft.au=Lynch%2C+Kristian+F&rft.au=L%C3%B6nnrot%2C+Maria&rft.au=Haller%2C+Michael+J&rft.date=2018-01-01&rft.pub=Springer+Nature+B.V&rft.issn=0012-186X&rft.eissn=1432-0428&rft.volume=61&rft.issue=1&rft.spage=193&rft.epage=202&rft_id=info:doi/10.1007%2Fs00125-017-4448-3&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-186X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-186X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-186X&client=summon